CTOs on the Move

Avectas

www.avectas.com

 
Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.avectas.com
  • 245 First Street Suite 1800
    Cambridge, MA USA 02142
  • Phone: 617.444.8593

Executives

Name Title Contact Details
Justin McCue
Chief Technology Officer Profile

Similar Companies

IGM Biosciences

IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM and IgA antibodies that improve the treatment of cancer and other diseases since 2010.

Acrometrix

Acrometrix is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vera Whole Health

Vera Whole Health is a market-leading healthcare service that delivers comprehensive, intelligent primary care to employees via employer-funded worksite clinics.   At the core of our philosophy is the belief that behavior change is the only sustainable way to help people live healthier. And we’ve found through experience and research that a person’s peer group is the primary motivator to that behavior change. That is why Vera Whole Health, in addition to offering primary care and health coaching to individuals, invests time and resources into helping companies change their health culture.

Biosearch Technologies

Biosearch Technologies is a Novato, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Microbion

Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.